↓ Skip to main content

The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies

Overview of attention for article published in Frontiers in Pharmacology, July 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

blogs
1 blog

Readers on

mendeley
164 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies
Published in
Frontiers in Pharmacology, July 2014
DOI 10.3389/fphar.2014.00167
Pubmed ID
Authors

Jun Xu, Xiao Liu, Yukinori Koyama, Ping Wang, Tian Lan, In-Gyu Kim, In H. Kim, Hsiao-Yen Ma, Tatiana Kisseleva

Abstract

Liver fibrosis results from dysregulation of normal wound healing, inflammation, activation of myofibroblasts, and deposition of extracellular matrix (ECM). Chronic liver injury causes death of hepatocytes and formation of apoptotic bodies, which in turn, release factors that recruit inflammatory cells (neutrophils, monocytes, macrophages, and lymphocytes) to the injured liver. Hepatic macrophages (Kupffer cells) produce TGFβ1 and other inflammatory cytokines that activate Collagen Type I producing myofibroblasts, which are not present in the normal liver. Secretion of TGFβ1 and activation of myofibroblasts play a critical role in the pathogenesis of liver fibrosis of different etiologies. Although the composition of fibrogenic myofibroblasts varies dependent on etiology of liver injury, liver resident hepatic stellate cells and portal fibroblasts are the major source of myofibroblasts in fibrotic liver in both experimental models of liver fibrosis and in patients with liver disease. Several studies have demonstrated that hepatic fibrosis can reverse upon cessation of liver injury. Regression of liver fibrosis is accompanied by the disappearance of fibrogenic myofibroblasts followed by resorption of the fibrous scar. Myofibroblasts either apoptose or inactivate into a quiescent-like state (e.g., stop collagen production and partially restore expression of lipogenic genes). Resolution of liver fibrosis is associated with recruitment of macrophages that secrete matrix-degrading enzymes (matrix metalloproteinase, collagenases) and are responsible for fibrosis resolution. However, prolonged/repeated liver injury may cause irreversible crosslinking of ECM and formation of uncleavable collagen fibers. Advanced fibrosis progresses to cirrhosis and hepatocellular carcinoma. The current review will summarize the role and contribution of different cell types to populations of fibrogenic myofibroblasts in fibrotic liver.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 164 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Italy 1 <1%
Argentina 1 <1%
Australia 1 <1%
Unknown 160 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 28 17%
Student > Ph. D. Student 25 15%
Student > Bachelor 22 13%
Student > Master 18 11%
Other 8 5%
Other 26 16%
Unknown 37 23%
Readers by discipline Count As %
Agricultural and Biological Sciences 36 22%
Medicine and Dentistry 33 20%
Biochemistry, Genetics and Molecular Biology 28 17%
Pharmacology, Toxicology and Pharmaceutical Science 11 7%
Immunology and Microbiology 7 4%
Other 11 7%
Unknown 38 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2014.
All research outputs
#5,875,378
of 22,769,322 outputs
Outputs from Frontiers in Pharmacology
#2,270
of 16,010 outputs
Outputs of similar age
#54,540
of 228,555 outputs
Outputs of similar age from Frontiers in Pharmacology
#16
of 69 outputs
Altmetric has tracked 22,769,322 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 16,010 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,555 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.